Clinical Trial Update: A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [Phase 3]

View source ↗

Summary

Phase 3 trial comparing eplerenone to placebo as add-on therapy in NYHA Class II heart failure; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• eplerenone (eplerenone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2011-06-27